カテゴリー： LP Information, 世界, 医療/バイオ

胆道がん（BTC）治療のグローバル市場予測2023-2029

◆英語タイトル：Global Biliary Tract Cancers (BTCs) Treatment Market Growth 2023-2029

LP Informationが発行した調査報告書（LP23DC01819）◆商品コード：LP23DC01819
◆発行会社（リサーチ会社）：LP Information
◆発行日：2023年11月
◆ページ数：114
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

LP Informationの最新刊調査レポート「胆道がん（BTC）治療のグローバル市場」は、過去の販売実績から2022年の世界の胆道がん（BTC）治療の総販売量を検討し、2023年から2029年の予測される胆道がん（BTC）治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の胆道がん（BTC）治療の市場規模を掲載し、XXX百万米ドル規模の世界の胆道がん（BTC）治療市場の詳細な分析を提供します。本インサイトレポートは、世界の胆道がん（BTC）治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の胆道がん（BTC）治療市場における各社の独自のポジションをより深く理解するために、胆道がん（BTC）治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の胆道がん（BTC）治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。胆道がん（BTC）治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。胆道がん（BTC）治療の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。胆道がん（BTC）治療のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

胆道がん（BTC）治療の世界主要メーカーとしては、Incyte Corporation、 Loxo Oncology、 Bayer、 Roche、 Genentech、 Agios Pharmaceuticals、 Servier Pharmaceuticals、 Merck Sharp & Dohme、 AstraZeneca、 Taiho Oncology、 Delcath Systems、 Eisai、 TransThera Sciences、 Basilea Pharmaceutica、 Zymeworks、 BeiGeneなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の胆道がん（BTC）治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場セグメンテーション】

この調査では胆道がん（BTC）治療市場をセグメンテーションし、種類別 (吸入式、皮下式、経口式、非経口式)、用途別 (病院薬局、オンライン薬局、小売薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：吸入式、皮下式、経口式、非経口式

・用途別区分：病院薬局、オンライン薬局、小売薬局

・地域別区分
南北アメリカ（米国、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の胆道がん（BTC）治療市場の10年間の市場状況・展望は？
・世界および地域別に見た胆道がん（BTC）治療市場成長の要因は何か？
・胆道がん（BTC）治療の市場機会はエンドマーケットの規模によってどのように変化するのか？
・胆道がん（BTC）治療のタイプ別、用途別の内訳は？
・新型コロナウイルスとロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：胆道がん（BTC）治療の年間販売量2018-2029、地域別現状・将来分析
・胆道がん（BTC）治療の種類別セグメント：吸入式、皮下式、経口式、非経口式
・胆道がん（BTC）治療の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・胆道がん（BTC）治療の用途別セグメント：病院薬局、オンライン薬局、小売薬局
・胆道がん（BTC）治療の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の胆道がん（BTC）治療市場
・企業別のグローバル胆道がん（BTC）治療市場データ：2018-2023年の年間販売量、市場シェア
・企業別の胆道がん（BTC）治療の年間売上：2018-2023年の売上、市場シェア
・企業別の胆道がん（BTC）治療販売価格
・主要企業の胆道がん（BTC）治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

胆道がん（BTC）治療の地域別レビュー
・地域別の胆道がん（BTC）治療市場規模2018-2023：年間販売量、売上
・主要国別の胆道がん（BTC）治療市場規模2018-2023：年間販売量、売上
・南北アメリカの胆道がん（BTC）治療販売の成長
・アジア太平洋の胆道がん（BTC）治療販売の成長
・ヨーロッパの胆道がん（BTC）治療販売の成長
・中東・アフリカの胆道がん（BTC）治療販売の成長

南北アメリカ市場
・南北アメリカの国別の胆道がん（BTC）治療販売量、売上（2018-2023）
・南北アメリカの胆道がん（BTC）治療の種類別販売量
・南北アメリカの胆道がん（BTC）治療の用途別販売量
・米国市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の胆道がん（BTC）治療販売量、売上（2018-2023）
・アジア太平洋の胆道がん（BTC）治療の種類別販売量
・アジア太平洋の胆道がん（BTC）治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の胆道がん（BTC）治療販売量、売上（2018-2023）
・ヨーロッパの胆道がん（BTC）治療の種類別販売量
・ヨーロッパの胆道がん（BTC）治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の胆道がん（BTC）治療販売量、売上（2018-2023）
・中東・アフリカの胆道がん（BTC）治療の種類別販売量
・中東・アフリカの胆道がん（BTC）治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・胆道がん（BTC）治療の製造コスト構造分析
・胆道がん（BTC）治療の製造プロセス分析
・胆道がん（BTC）治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・胆道がん（BTC）治療の主要なグローバル販売業者
・胆道がん（BTC）治療の主要なグローバル顧客

地域別の胆道がん（BTC）治療市場予測レビュー
・地域別の胆道がん（BTC）治療市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・胆道がん（BTC）治療の種類別市場規模予測
・胆道がん（BTC）治療の用途別市場規模予測

主要企業分析
Incyte Corporation、 Loxo Oncology、 Bayer、 Roche、 Genentech、 Agios Pharmaceuticals、 Servier Pharmaceuticals、 Merck Sharp & Dohme、 AstraZeneca、 Taiho Oncology、 Delcath Systems、 Eisai、 TransThera Sciences、 Basilea Pharmaceutica、 Zymeworks、 BeiGene
・企業情報
・胆道がん（BTC）治療製品
・胆道がん（BTC）治療販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Biliary Tract Cancers (BTCs) Treatment market size is projected to grow from US$ 3010.1 million in 2022 to US$ 4001.1 million in 2029; it is expected to grow at a CAGR of 4.1% from 2023 to 2029.
United States market for Biliary Tract Cancers (BTCs) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Biliary Tract Cancers (BTCs) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Biliary Tract Cancers (BTCs) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Biliary Tract Cancers (BTCs) Treatment players cover Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme and AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. The Biliary Tract Cancers (BTCs) Treatment market offers a range of products and services for its effective management and treatments including medications such as chemotherapy, chemotherapy drugs such as gemcitabine and cisplatin, surgery, and radiation therapy.
LPI (LP Information)’ newest research report, the “Biliary Tract Cancers (BTCs) Treatment Industry Forecast” looks at past sales and reviews total world Biliary Tract Cancers (BTCs) Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Biliary Tract Cancers (BTCs) Treatment sales for 2023 through 2029. With Biliary Tract Cancers (BTCs) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biliary Tract Cancers (BTCs) Treatment industry.
This Insight Report provides a comprehensive analysis of the global Biliary Tract Cancers (BTCs) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biliary Tract Cancers (BTCs) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biliary Tract Cancers (BTCs) Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biliary Tract Cancers (BTCs) Treatment and breaks down the forecast by route, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biliary Tract Cancers (BTCs) Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Biliary Tract Cancers (BTCs) Treatment market by product route, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by route
Inhalation
Subcutaneous
Oral
Parenteral
Segmentation by application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Incyte Corporation
Loxo Oncology
Bayer
Roche
Genentech
Agios Pharmaceuticals
Servier Pharmaceuticals
Merck Sharp & Dohme
AstraZeneca
Taiho Oncology
Delcath Systems
Eisai
TransThera Sciences
Basilea Pharmaceutica
Zymeworks
BeiGene
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biliary Tract Cancers (BTCs) Treatment market?
What factors are driving Biliary Tract Cancers (BTCs) Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biliary Tract Cancers (BTCs) Treatment market opportunities vary by end market size?
How does Biliary Tract Cancers (BTCs) Treatment break out route, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biliary Tract Cancers (BTCs) Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Biliary Tract Cancers (BTCs) Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Biliary Tract Cancers (BTCs) Treatment by Country/Region, 2018, 2022 & 2029
2.2 Biliary Tract Cancers (BTCs) Treatment Segment by Route
2.2.1 Inhalation
2.2.2 Subcutaneous
2.2.3 Oral
2.2.4 Parenteral
2.3 Biliary Tract Cancers (BTCs) Treatment Sales by Route
2.3.1 Global Biliary Tract Cancers (BTCs) Treatment Sales Market Share by Route (2018-2023)
2.3.2 Global Biliary Tract Cancers (BTCs) Treatment Revenue and Market Share by Route (2018-2023)
2.3.3 Global Biliary Tract Cancers (BTCs) Treatment Sale Price by Route (2018-2023)
2.4 Biliary Tract Cancers (BTCs) Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Online Pharmacies
2.4.3 Retail Pharmacies
2.5 Biliary Tract Cancers (BTCs) Treatment Sales by Application
2.5.1 Global Biliary Tract Cancers (BTCs) Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Biliary Tract Cancers (BTCs) Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Biliary Tract Cancers (BTCs) Treatment Sale Price by Application (2018-2023)
3 Global Biliary Tract Cancers (BTCs) Treatment by Company
3.1 Global Biliary Tract Cancers (BTCs) Treatment Breakdown Data by Company
3.1.1 Global Biliary Tract Cancers (BTCs) Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Biliary Tract Cancers (BTCs) Treatment Sales Market Share by Company (2018-2023)
3.2 Global Biliary Tract Cancers (BTCs) Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Biliary Tract Cancers (BTCs) Treatment Revenue by Company (2018-2023)
3.2.2 Global Biliary Tract Cancers (BTCs) Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Biliary Tract Cancers (BTCs) Treatment Sale Price by Company
3.4 Key Manufacturers Biliary Tract Cancers (BTCs) Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biliary Tract Cancers (BTCs) Treatment Product Location Distribution
3.4.2 Players Biliary Tract Cancers (BTCs) Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Biliary Tract Cancers (BTCs) Treatment by Geographic Region
4.1 World Historic Biliary Tract Cancers (BTCs) Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Biliary Tract Cancers (BTCs) Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Biliary Tract Cancers (BTCs) Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Biliary Tract Cancers (BTCs) Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Biliary Tract Cancers (BTCs) Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Biliary Tract Cancers (BTCs) Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Biliary Tract Cancers (BTCs) Treatment Sales Growth
4.4 APAC Biliary Tract Cancers (BTCs) Treatment Sales Growth
4.5 Europe Biliary Tract Cancers (BTCs) Treatment Sales Growth
4.6 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment Sales Growth
5 Americas
5.1 Americas Biliary Tract Cancers (BTCs) Treatment Sales by Country
5.1.1 Americas Biliary Tract Cancers (BTCs) Treatment Sales by Country (2018-2023)
5.1.2 Americas Biliary Tract Cancers (BTCs) Treatment Revenue by Country (2018-2023)
5.2 Americas Biliary Tract Cancers (BTCs) Treatment Sales by Route
5.3 Americas Biliary Tract Cancers (BTCs) Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biliary Tract Cancers (BTCs) Treatment Sales by Region
6.1.1 APAC Biliary Tract Cancers (BTCs) Treatment Sales by Region (2018-2023)
6.1.2 APAC Biliary Tract Cancers (BTCs) Treatment Revenue by Region (2018-2023)
6.2 APAC Biliary Tract Cancers (BTCs) Treatment Sales by Route
6.3 APAC Biliary Tract Cancers (BTCs) Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Biliary Tract Cancers (BTCs) Treatment by Country
7.1.1 Europe Biliary Tract Cancers (BTCs) Treatment Sales by Country (2018-2023)
7.1.2 Europe Biliary Tract Cancers (BTCs) Treatment Revenue by Country (2018-2023)
7.2 Europe Biliary Tract Cancers (BTCs) Treatment Sales by Route
7.3 Europe Biliary Tract Cancers (BTCs) Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment by Country
8.1.1 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment Sales by Route
8.3 Middle East & Africa Biliary Tract Cancers (BTCs) Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biliary Tract Cancers (BTCs) Treatment
10.3 Manufacturing Process Analysis of Biliary Tract Cancers (BTCs) Treatment
10.4 Industry Chain Structure of Biliary Tract Cancers (BTCs) Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biliary Tract Cancers (BTCs) Treatment Distributors
11.3 Biliary Tract Cancers (BTCs) Treatment Customer
12 World Forecast Review for Biliary Tract Cancers (BTCs) Treatment by Geographic Region
12.1 Global Biliary Tract Cancers (BTCs) Treatment Market Size Forecast by Region
12.1.1 Global Biliary Tract Cancers (BTCs) Treatment Forecast by Region (2024-2029)
12.1.2 Global Biliary Tract Cancers (BTCs) Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Biliary Tract Cancers (BTCs) Treatment Forecast by Route
12.7 Global Biliary Tract Cancers (BTCs) Treatment Forecast by Application
13 Key Players Analysis
13.1 Incyte Corporation
13.1.1 Incyte Corporation Company Information
13.1.2 Incyte Corporation Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.1.3 Incyte Corporation Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Incyte Corporation Main Business Overview
13.1.5 Incyte Corporation Latest Developments
13.2 Loxo Oncology
13.2.1 Loxo Oncology Company Information
13.2.2 Loxo Oncology Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.2.3 Loxo Oncology Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Loxo Oncology Main Business Overview
13.2.5 Loxo Oncology Latest Developments
13.3 Bayer
13.3.1 Bayer Company Information
13.3.2 Bayer Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.3.3 Bayer Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Bayer Main Business Overview
13.3.5 Bayer Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.4.3 Roche Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Genentech
13.5.1 Genentech Company Information
13.5.2 Genentech Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.5.3 Genentech Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Genentech Main Business Overview
13.5.5 Genentech Latest Developments
13.6 Agios Pharmaceuticals
13.6.1 Agios Pharmaceuticals Company Information
13.6.2 Agios Pharmaceuticals Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.6.3 Agios Pharmaceuticals Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Agios Pharmaceuticals Main Business Overview
13.6.5 Agios Pharmaceuticals Latest Developments
13.7 Servier Pharmaceuticals
13.7.1 Servier Pharmaceuticals Company Information
13.7.2 Servier Pharmaceuticals Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.7.3 Servier Pharmaceuticals Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Servier Pharmaceuticals Main Business Overview
13.7.5 Servier Pharmaceuticals Latest Developments
13.8 Merck Sharp & Dohme
13.8.1 Merck Sharp & Dohme Company Information
13.8.2 Merck Sharp & Dohme Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.8.3 Merck Sharp & Dohme Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Merck Sharp & Dohme Main Business Overview
13.8.5 Merck Sharp & Dohme Latest Developments
13.9 AstraZeneca
13.9.1 AstraZeneca Company Information
13.9.2 AstraZeneca Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.9.3 AstraZeneca Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AstraZeneca Main Business Overview
13.9.5 AstraZeneca Latest Developments
13.10 Taiho Oncology
13.10.1 Taiho Oncology Company Information
13.10.2 Taiho Oncology Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.10.3 Taiho Oncology Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Taiho Oncology Main Business Overview
13.10.5 Taiho Oncology Latest Developments
13.11 Delcath Systems
13.11.1 Delcath Systems Company Information
13.11.2 Delcath Systems Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.11.3 Delcath Systems Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Delcath Systems Main Business Overview
13.11.5 Delcath Systems Latest Developments
13.12 Eisai
13.12.1 Eisai Company Information
13.12.2 Eisai Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.12.3 Eisai Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Eisai Main Business Overview
13.12.5 Eisai Latest Developments
13.13 TransThera Sciences
13.13.1 TransThera Sciences Company Information
13.13.2 TransThera Sciences Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.13.3 TransThera Sciences Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 TransThera Sciences Main Business Overview
13.13.5 TransThera Sciences Latest Developments
13.14 Basilea Pharmaceutica
13.14.1 Basilea Pharmaceutica Company Information
13.14.2 Basilea Pharmaceutica Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.14.3 Basilea Pharmaceutica Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Basilea Pharmaceutica Main Business Overview
13.14.5 Basilea Pharmaceutica Latest Developments
13.15 Zymeworks
13.15.1 Zymeworks Company Information
13.15.2 Zymeworks Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.15.3 Zymeworks Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Zymeworks Main Business Overview
13.15.5 Zymeworks Latest Developments
13.16 BeiGene
13.16.1 BeiGene Company Information
13.16.2 BeiGene Biliary Tract Cancers (BTCs) Treatment Product Portfolios and Specifications
13.16.3 BeiGene Biliary Tract Cancers (BTCs) Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 BeiGene Main Business Overview
13.16.5 BeiGene Latest Developments
14 Research Findings and Conclusion



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 胆道がん（BTC）治療のグローバル市場予測2023-2029(Global Biliary Tract Cancers (BTCs) Treatment Market Growth 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 胆道&膵臓ステントのグローバル市場予測2023-2029
  • 伝染性軟属腫（MC）治療のグローバル市場予測2023-2029
  • モリブデン補因子欠乏 A型（MoCoD-A）治療のグローバル市場予測2023-2029
  • 意義不明の単クローン性高分子免疫グロブリン血症（MGUS）治療のグローバル市場予測2023-2029
  • 胆道ドレナージチューブのグローバル市場予測2023-2029